rosiglitazone has been researched along with oroxylin a-7-o-glucuronide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, S; Chen, Q; Cui, M; Jiang, H; Kang, N; Li, D; Qiu, F; Wang, T; Wang, Z; Zhou, J | 1 |
1 other study(ies) available for rosiglitazone and oroxylin a-7-o-glucuronide
| Article | Year |
|---|---|
Baicalin and its metabolites suppresses gluconeogenesis through activation of AMPK or AKT in insulin resistant HepG-2 cells.
Topics: AMP-Activated Protein Kinases; Cell Survival; Dose-Response Relationship, Drug; Flavonoids; Gluconeogenesis; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Molecular Structure; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |